Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.

Abstract: A process comprising reacting a benzoic acid with a glycol ether in the presence of phosphoric acid to produce a glycol ether ester product having low color, low odor, and low VOC content.

Abstract: A process comprising reacting a benzoic acid with a glycol ether in the presence of phosphoric acid to produce a glycol ether ester product having low color, low odor, and low VOC content.

Abstract: A process comprising reacting a mono- or di-carboxylic acid and/or acid anhydride with a glycol ether in the presence of phosphoric acid to produce a glycol ether ester product having low color and low VOC content.

Abstract: A dispersant includes the reaction product of an amine and at least one equivalent of glycidyl ether where the amine is selected from a group consisting of aminoethylpiperazine, bis(2-(piperazin-1-yl)ethyl)amine, 4,4?-methylenebiscyclohexylamine, m-xylenediamine, diethylenetriamine, and triethylenetetramine and where the glycidyl ether has the structure (A), where R is selected from aromatic carbon chains, non-aromatic carbon chains and polyalkylene glycol groups. The dispersant is useful in a lubricant with a base oil for increasing soot dispersibility of the lubricant.

Abstract: The present invention relates to an improved bitumen recovery process from oil sands. The oil sands may be surface mined and transported to a treatment area or may be treated directly by means of an in situ process of oil sand deposits that are located too deep for strip mining. Specifically, the present invention involves the step of treating oil sands with a propylene oxide capped glycol ether described by the structure: RO—(C2H4O)n—CH2CH(CH3)OH wherein R is a linear, branched, or cyclic alkyl, phenyl, alkyl phenyl group and n is 1 to 10.

Abstract: A process for the production of 2-butoxyethyl benzoate from benzoic acid and 2-butoxy ethanol wherein at least a portion of the crude reaction product is fed to a distillation column comprising a dividing wall or a pasteurizing section.

Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.

Abstract: A process comprising contacting deionized water with one or more Strecker sulfonation reaction products of one or more halogenated alkyl ethers in the presence of sulfite, wherein the one or more Strecker sulfonation reaction products each comprise one or more inorganic salts on a dry basis and one or more surfactant components, form a filtration mixture; loading the filtration mixture into a high pressure filtration system containing a membrane having a membrane molecular weight cutoff allowing preferential passage of the inorganic salts, for example, of greater than or equal to 200 Daltons; wherein the high pressure filtration system is operated at a pressure greater than ambient pressure and is configured to cause crossflow of the filtration mixture along a surface of the membrane resulting in a permeate solution which substantially passes through the membrane and a retentate solution which substantially does not pass through the membrane; wherein the permeate comprises less than or equal to 15 weight perc

Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.

Abstract: Disclosed are a process and an apparatus for using an olefin as an azeotropic entrainer to isolate a target organic compound from a waste stream. The olefin may be, for example, 1-decene, 1-dodecene, or 1-tetradecene. The target organic compound may be 1,3-dichloro-2-propanol in waste stream comprising a 2,2?-oxybis(1-chloropropane).

Abstract: A process for the production of 2-butoxyethyl benzoate from benzoic acid and 2-butoxy ethanol wherein at least a portion of the crude reaction product is fed to a distillation column comprising a dividing wall or a pasteurizing section.

Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.

Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.

Abstract: A process including contacting one or more Strecker sulfonation reaction products of one or more halogenated alkyl ethers in the presence of sulfite with one or more polar water soluble organic solvents selected from acetone, methyl ethyl ketone, the C2-C5 alkyl alcohols, and the like, to form an extraction mixture; allowing the extraction mixture to separate into an aqueous phase and an organic phase; and separating the aqueous phase from the organic phase; wherein the one or more Strecker sulfonation reaction products each comprise at least 30 percent by weight of one or more inorganic salts and the organic phase following separation comprises less than 20 percent by weight of one or more inorganic salts, is provided.

Abstract: The invention relates to processes for the etherification of olefins with alcohols. According to one aspect, a heterogeneous etherification catalyst is used under conditions that permit limiting the contact time between the desired product and the catalyst, thereby mitigation reverse reactions. According to a second aspect, a recycling process is used that significantly increases the yield of desired product.

Abstract: A process comprising contacting deionized water with one or more Strecker sulfonation reaction products of one or more halogenated alkyl ethers in the presence of sulfite, wherein the one or more Strecker sulfonation reaction products each comprise one or more inorganic salts on a dry basis and one or more surfactant components, form a filtration mixture; loading the filtration mixture into a high pressure filtration system containing a membrane having a membrane molecular weight cutoff allowing preferential passage of the inorganic salts, for example, of greater than or equal to 200 Daltons; wherein the high pressure filtration system is operated at a pressure greater than ambient pressure and is configured to cause crossflow of the filtration mixture along a surface of the membrane resulting in a permeate solution which substantially passes through the membrane and a retentate solution which substantially does not pass through the membrane; wherein the permeate comprises less than or equal to 15 weight perc

Abstract: Provided are new functionalized surfactants and methods of their preparation and use. The surfactants are compounds of formula I: wherein R1, R2, and R3 are as defined herein.

Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.

Abstract: Phenolic glycol ethers, e.g., ethylene glycol phenyl ether, are prepared by a continuous, nonaqueous process comprising the steps of (A) contacting under isothermal reactive conditions in a first reactor or reaction zone an alkylene oxide, e.g., ethylene oxide, with (i) a stoichiometric molar excess of a phenolic compound, e.g., phenol, and (ii) a catalytic amount of a base, e.g., sodium hydroxide, homogeneously dispersed throughout the phenolic compound, to form a first intermediate phenolic glycol ether product, (Bj transferring the first intermediate phenolic glycol ether product to a second reactor or reaction zone, and (C) subjecting the first intermediate phenolic glycol ether product to adiabatic reactive conditions in the second reactor or reaction zone to form a second intermediate phenolic glycol ether product comprising phenolic glycol ether, unreacted phenolic compound, catalyst, water and byproduct glycols.